Shinsuke Hanatani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2216302/publications.pdf

Version: 2024-02-01

		516710	501196
46	868	16	28
papers	citations	h-index	g-index

46	46	46	3320
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1285-1294.	2.0	7
2	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Cardiovascular Intervention and Therapeutics, 2022, 37, 60-65.	2.3	4
3	Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. Journal of Cardiology, 2022, 79, 50-57.	1.9	8
4	HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. Korean Journal of Internal Medicine, 2022, 37, 96-108.	1.7	10
5	Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1227-1235.	2.6	4
6	Cardiac computed tomographyâ€derived myocardial tissue characterization after anthracycline treatment. ESC Heart Failure, 2022, 9, 1792-1800.	3.1	3
7	Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. ESC Heart Failure, 2022, 9, 1976-1986.	3.1	6
8	Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 76, 513-522.e3.	1.1	1
9	A simple staging system using biomarkers for wildâ€type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2022, 9, 1731-1739.	3.1	5
10	Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive ^{99 m}Tc-Labeled Pyrophosphate Scintigraphy Findings. Circulation Journal, 2022, 86, 1113-1120.	1.6	4
11	Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wildâ€Type Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	3.7	4
12	Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2021, 325, 121-126.	1.7	9
13	Sirt7 Deficiency Attenuates Neointimal Formation Following Vascular Injury by Modulating Vascular Smooth Muscle Cell Proliferation. Circulation Journal, 2021, 85, 2232-2240.	1.6	8
14	Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention.. Thrombosis Research, 2021, 200, 141-148.	1.7	6
15	Preclinical diagnosis of wild-type transthyretin amyloid cardiomyopathy in a patient undergoing carpal tunnel release. Journal of Cardiology Cases, 2021, 24, 250-253.	0.5	0
16	Prognostic significance of liver stiffness assessed by fibrosisâ€4 index in patients with heart failure. ESC Heart Failure, 2021, 8, 3809-3821.	3.1	9
17	A simple method of sarcopenia detection can predict adverse cardiovascular events in patients with abdominal obesity. International Journal of Obesity, 2021, 45, 2214-2220.	3.4	8
18	HE4 Predicts Progressive Fibrosis and Cardiovascular Events in Patients With Dilated Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021069.	3.7	14

#	Article	IF	Citations
19	Prognostic value of left atrial strain in patients with wildâ€type transthyretin amyloid cardiomyopathy. ESC Heart Failure, 2021, 8, 5316-5326.	3.1	9
20	Abstract 10841: Clinical Significance of Left Atrial Function Estimated by Two Dimensional Speckle Tracking Echocardiography for Diagnosis of Concomitant Transthyretin Amyloid Cardiomyopathy in Patients with Aortic Stenosis. Circulation, 2021, 144, .	1.6	0
21	Cardiomyocyte Sirt (Sirtuin) 7 Ameliorates Stress-Induced Cardiac Hypertrophy by Interacting With and Deacetylating GATA4. Hypertension, 2020, 75, 98-108.	2.7	74
22	Clinical characteristics and natural history of wildâ€type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2020, 7, 2829-2837.	3.1	32
23	Clinical significance of diastolic late mitral annular velocity in heart failure with preserved ejection fraction. International Journal of Cardiology, 2020, 316, 145-151.	1.7	5
24	Cytotoxin-associated gene-A-seropositivity and Interleukin-1 polymorphisms influence adverse cardiovascular events. IJC Heart and Vasculature, 2020, 27, 100498.	1.1	2
25	Doubleâ€chambered right ventricle complicated by hypertrophic obstructive cardiomyopathy diagnosed as Noonan syndrome. ESC Heart Failure, 2020, 7, 721-726.	3.1	3
26	Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture. Hemodialysis International, 2020, 24, 202-211.	0.9	8
27	Combination of Commonly Examined Parameters Is a Useful Predictor of Positive ^{99 m}Tc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis. Circulation Journal, 2019, 83, 1698-1708.	1.6	33
28	Coronary blood flow volume change is negatively associated with platelet aggregability in patients with non-obstructive ischemic heart disease who have no anti-platelet agents. International Journal of Cardiology, 2019, 277, 3-7.	1.7	1
29	Grip strength predicts cardiac adverse events in patients with cardiac disorders: an individual patient pooled meta-analysis. Heart, 2019, 105, 834-841.	2.9	61
30	Nonâ€Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. ESC Heart Failure, 2019, 6, 122-130.	3.1	12
31	Reply to letter to the editor: â€œA simple sarcopenia screening test predicts future adverse events in patients with heart failureâ€• International Journal of Cardiology, 2018, 256, 28.	1.7	0
32	Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease. International Journal of Cardiology, 2018, 268, 216-221.	1.7	45
33	Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 290-300.	4.0	53
34	Akt1-Mediated Muscle Growth Promotes Blood Flow Recovery After Hindlimb Ischemia by Enhancing Heme Oxygenase-1 in Neighboring Cells. Circulation Journal, 2018, 82, 2905-2912.	1.6	8
35	Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients. American Journal of Hypertension, 2018, 31, 1098-1105.	2.0	22
36	Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant. Thrombosis Journal, 2017, 15, 4.	2.1	5

#	Article	IF	Citations
37	Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy. Heart and Vessels, 2017, 32, 708-713.	1.2	3
38	A simple sarcopenia screening test predicts future adverse events in patients with heart failure. International Journal of Cardiology, 2016, 215, 301-306.	1.7	55
39	Fragmented QRS complex is a diagnostic tool in patients with left ventricular diastolic dysfunction. Heart and Vessels, 2016, 31, 563-567.	1.2	20
40	High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart and Vessels, 2016, 31, 52-59.	1.2	30
41	Expression of Let-7 family microRNAs in skin correlates negatively with severity of pulmonary hypertension in patients with systemic scleroderma. IJC Heart and Vasculature, 2015, 8, 98-102.	1.1	19
42	Sirt7 Contributes to Myocardial Tissue Repair by Maintaining Transforming Growth Factor-Î² Signaling Pathway. Circulation, 2015, 132, 1081-1093.	1.6	88
43	Akt1-Mediated Fast/Glycolytic Skeletal Muscle Growth Attenuates Renal Damage in Experimental Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 2800-2811.	6.1	49
44	Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts. Heart and Vessels, 2014, 29, 231-237.	1.2	21
45	Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2014, 30, 338-344.	1.7	64
46	Akt1â€“Mediated Skeletal Muscle Growth Attenuates Cardiac Dysfunction and Remodeling After Experimental Myocardial Infarction. Circulation: Heart Failure, 2012, 5, 116-125.	3.9	36